Carboplat10 mg/ml

Carboplat is a platinum-based chemotherapy agent used in the treatment of certain cancers, primarily as part of physician-supervised combination or single-agent regimens.

Established / FDA-approved uses

• Initial treatment of advanced ovarian carcinoma — Carboplat is indicated, in combination with other approved chemotherapeutic agents (commonly cyclophosphamide), for the initial treatment of advanced epithelial ovarian carcinoma.
• Palliative treatment of recurrent ovarian carcinoma — Carboplat is indicated as secondary/palliative therapy for patients with ovarian carcinoma recurrent after prior chemotherapy, including patients previously treated with cisplatin.

Guideline-supported / commonly used off-label uses

Carboplat is widely used, based on strong clinical evidence and inclusion in oncology treatment guidelines, in combination regimens (often with a taxane such as paclitaxel) for:

• Non-small cell lung cancer (NSCLC)
• Small cell lung cancer (SCLC)
• Head and neck squamous cell carcinoma
• Cervical cancer
• Endometrial cancer
• Bladder (urothelial) cancer
• Triple-negative breast cancer (in select combination regimens)
• Germ cell tumors and certain pediatric malignancies (e.g., retinoblastoma, brain tumors), used under specialist pediatric oncology protocols

These non-ovarian uses are considered off-label relative to the original approved labeling but are standard of care in many oncology guidelines and must only be prescribed by an oncologist.

Each mL of Carboplatin injection typically contains Carboplatin 10 mg as the active ingredient, formulated as a sterile aqueous solution for intravenous infusion. Common presentations include single-dose or multi-dose vials (e.g., 50 mg/5 mL, 150 mg/15 mL, 450 mg/45 mL, 600 mg/60 mL), each at a concentration of 10 mg/mL. No preservative is present in most single-dose formulations; check the specific product label for excipients.

Carboplat is a second-generation platinum coordination compound (a cisplatin analogue) used as a cytotoxic antineoplastic (chemotherapy) agent. It is chemically related to cisplatin but generally causes less nephrotoxicity, neurotoxicity, and ototoxicity, with the trade-off of more pronounced myelosuppression, particularly thrombocytopenia.

Carboplat is supplied as a clear, colorless, sterile aqueous solution for intravenous infusion and must be administered only under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Carboplat belongs to the therapeutic class of platinum-based antineoplastic (alkylating-like) agents, used in cytotoxic cancer chemotherapy.

Mechanism of action: Carboplatin is a platinum coordination compound that does not directly alkylate DNA but produces effects similar to alkylating agents. After intracellular aquation (activation), the platinum atom binds covalently to DNA, primarily forming inter- and intra-strand cross-links between adjacent guanine bases. These cross-links disrupt DNA structure and function, inhibiting DNA replication and transcription, ultimately leading to cell-cycle arrest (predominantly in the G2/M phase) and apoptosis of rapidly dividing malignant cells.

Pharmacokinetics: Following intravenous administration, free (ultrafilterable) platinum from Carboplatin is widely distributed and shows biphasic plasma elimination, with initial and post-distribution half-lives. Carboplatin is primarily eliminated by renal excretion; the total body clearance of Carboplatin correlates closely with glomerular filtration rate (GFR), which is the basis for GFR-based (Calvert formula) dosing. Unlike cisplatin, Carboplatin undergoes minimal protein binding when initially administered, though platinum becomes irreversibly bound to plasma proteins over time.

Carboplat is given exclusively by intravenous infusion in a hospital or specialized oncology infusion setting, prepared and administered by trained oncology healthcare staff. It must never be given intramuscularly, subcutaneously, or by any route other than IV infusion. See Dosage and Administration for infusion technique and compatibility precautions (e.g., avoiding aluminum-containing equipment).

Carboplat has several clinically significant drug interactions that must be considered before and during treatment:

• Nephrotoxic drugs (e.g., aminoglycoside antibiotics, amphotericin B, contrast media): Concomitant use may increase the risk of nephrotoxicity and, particularly with aminoglycosides, ototoxicity; renal function and hearing should be monitored closely.
• Other myelosuppressive drugs or radiotherapy: Concurrent use increases the risk and severity of bone marrow suppression; blood counts require close monitoring.
• Live vaccines: Concomitant vaccination with live or live-attenuated vaccines is not recommended during Carboplat therapy due to immunosuppression, and may result in a serious or fatal infection.
• Phenytoin/other anticonvulsants: Chemotherapy including Carboplat may reduce absorption or increase clearance of phenytoin, leading to loss of seizure control; conversely, some anticonvulsants may affect chemotherapy efficacy.
• Warfarin and other anticoagulants: Chemotherapy can potentiate anticoagulant effect; more frequent INR monitoring is recommended.

Carboplat commonly causes dose-related adverse effects, most notably on the bone marrow and gastrointestinal system.

Very common

• Myelosuppression: thrombocytopenia (dose-limiting), neutropenia, leukopenia, anemia (may require transfusion)
• Nausea and vomiting (often severe without antiemetic prophylaxis)
• Electrolyte disturbances (hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia)
• Fatigue, asthenia

Common

• Peripheral neuropathy (more frequent in patients over 65 years or those pretreated with cisplatin)
• Ototoxicity (hearing impairment, tinnitus)
• Elevated liver enzymes
• Alopecia (less common than with some other chemotherapy agents)
• Infection (secondary to neutropenia)

Serious / rare

• Anaphylactic-like hypersensitivity reactions (can occur within minutes of administration; more common with repeated courses) — see Precautions and Warnings.
• Hemorrhage related to severe thrombocytopenia
• Visual disturbances, including rare reports of loss of vision, generally with doses higher than recommended
• Hemolytic uremic syndrome (rare)
• Secondary malignancies (rare, with long-term use)

Pregnancy: Carboplat can cause fetal harm when administered to a pregnant woman, based on its mechanism of action and animal reproduction studies showing embryotoxicity and teratogenicity. Carboplat should be avoided in pregnancy, especially the first trimester; it should only be used if clearly needed and if the potential benefit to the mother justifies the potential risk to the fetus, and only after thorough discussion with an oncologist. Women of reproductive potential should use effective contraception during and for a period after treatment; men being treated should also use effective contraception, as Carboplat may cause genetic damage to sperm.

Lactation: It is not known whether Carboplat is excreted in human breast milk; because many chemotherapy drugs are excreted in breast milk and because of the potential for serious adverse effects in nursing infants, breastfeeding should be discontinued during Carboplat treatment. Consult a physician before resuming breastfeeding after therapy ends.

Carboplat must be administered only under the supervision of a physician experienced in cancer chemotherapy, in a facility equipped to monitor and manage its toxicities.

• Bone marrow suppression: Dose-related and can be severe, especially thrombocytopenia; this is the dose-limiting toxicity. Complete blood counts should be monitored frequently during treatment, and dosing should not be repeated until blood counts recover.
• Anaphylactic-like reactions: May occur within minutes of Carboplat administration and are more likely with repeated courses; symptoms may include facial swelling, wheezing, tachycardia, and hypotension. Facilities for treating anaphylaxis (epinephrine, corticosteroids, antihistamines, oxygen) must be immediately available.
• Renal function: Dose must be individualized based on renal function (Calvert formula); patients with impaired renal function are at increased risk of severe myelosuppression.
• Ototoxicity and neurotoxicity: Risk is increased in patients over 65 years, those previously treated with cisplatin, or those receiving other ototoxic/neurotoxic drugs concurrently. Baseline and periodic audiometric testing is recommended for patients at higher risk.
• Vomiting: Highly emetogenic; routine antiemetic premedication is recommended.
• Visual disturbances: Rare reports of vision loss have occurred, generally at doses exceeding recommended levels.
• Handling: Carboplat is a cytotoxic drug; procedures for proper handling and disposal of anticancer drugs should be followed by trained personnel. Avoid contact with skin or mucous membranes; if contact occurs, wash thoroughly with water.
• Fertility: Carboplat may impair fertility in both men and women; fertility preservation counseling should be offered before treatment where feasible.

There is no known specific antidote for Carboplat overdose. Overdosage is expected to result in exaggeration of known adverse effects, primarily severe and prolonged bone marrow suppression (with risk of serious infection and bleeding), and potentially hepatic toxicity, ototoxicity, and visual disturbances. Deaths have been reported with overdose.

If overdose is suspected, seek immediate medical attention or contact emergency services/a poison control center right away. Management should occur in a specialized medical facility and typically involves close monitoring of blood counts and organ function, supportive care, and treatment of complications such as infection, bleeding, or electrolyte abnormalities as they arise, under the direction of an oncologist.

Store unopened vials at room temperature, between 20-25°C (68-77°F), protected from light. Do not freeze. Once diluted for infusion, use within the time specified by the manufacturer/pharmacy (typically within 8 hours at room temperature) and discard any unused solution. Keep out of reach of children. This medicine should be handled and disposed of according to hospital cytotoxic waste protocols.

Pediatric use

The safety and effectiveness of Carboplat in pediatric patients for its approved ovarian carcinoma indication have not been formally established. However, Carboplat is used in pediatric oncology (e.g., retinoblastoma, certain brain tumors, neuroblastoma, germ cell tumors) under specialist pediatric oncology protocols, with dosing individualized by body surface area or weight and renal function. Ototoxicity risk may be increased in children, particularly when combined with other ototoxic agents.

Geriatric use

Elderly patients (over 65 years) are more likely to experience severe thrombocytopenia and peripheral or ototoxic neurotoxicity. Renal function should be carefully assessed (age-related decline in GFR) and used to guide Calvert formula dosing; more frequent monitoring is recommended in this population.

Renal impairment

Carboplat dosing must be adjusted based on renal function (Calvert formula, or reduced starting doses for creatinine clearance below 60 mL/min); patients with severe renal impairment require specialist oncology supervision, and safety data in patients with creatinine clearance below 15 mL/min are limited.

Hepatic impairment

No specific dose adjustment guidelines are well established for hepatic impairment; use with caution and close monitoring of liver function.

Duration of Carboplat treatment is determined by the treating oncologist and depends on the cancer type, treatment protocol, response to therapy, and tolerability. Typical regimens involve cycles repeated every 3-4 weeks (e.g., 6 cycles for initial ovarian carcinoma combination therapy), with treatment continued, interrupted, or dose-adjusted based on periodic assessment of tumor response and hematologic/organ toxicity. Treatment should not be repeated more frequently than every 4 weeks (single-agent) unless directed by the oncologist, and blood counts must recover to acceptable levels before the next cycle.

Carboplat for injection is available both as a ready-to-use aqueous solution (10 mg/mL) and, in some markets, as a lyophilized powder for reconstitution. Where a lyophilized powder form is used, it should be reconstituted with Sterile Water for Injection, 5% Dextrose Injection, or 0.9% Sodium Chloride Injection according to the manufacturer's instructions to achieve a concentration of 10 mg/mL, using only non-aluminum equipment, and further diluted for IV infusion with 5% Dextrose or 0.9% Sodium Chloride as needed. Reconstituted/diluted solutions should be used promptly and inspected visually for particulate matter and discoloration before administration.

Carboplatin is classified as a platinum-based antineoplastic agent (alkylating-like cytotoxic chemotherapy drug).

Carboplatin works by forming platinum-DNA cross-links (inter- and intra-strand) after intracellular activation, which disrupts DNA structure and function, blocking DNA replication and transcription. This leads to cell-cycle arrest, predominantly at the G2/M phase, and triggers apoptosis (programmed cell death) preferentially in rapidly dividing malignant cells.

D

Carboplat is not formally approved for pediatric use in its labeled ovarian carcinoma indication, and safety and efficacy for that indication have not been established in children. Nonetheless, Carboplat is used off-label, under specialist pediatric oncology protocols, in the treatment of certain childhood cancers such as retinoblastoma, central nervous system tumors, neuroblastoma, and germ cell tumors, with dosing carefully individualized by body surface area/weight and renal function, and with close monitoring for hearing loss (ototoxicity) and myelosuppression, which may affect children more than adults.